WVE (wavelifesciences.com) Earnings per share growth rate in current year
Wave Life Sciences possesses colossal potential for scaling RNA therapeutics by creating series of affordable drugs. Annual EPS variability confirms the strength of this trend, where the value of 8.30 expresses the metric level. The business relies on protected patents and external CROs, while expansion is driven by partnerships with behemoths in the unsaturated precision medicine segment.
Financial and market metric breakdowns for Wave Life Sciences Ltd (WVE)
- current price and projected stock value:
- business market valuation indicators:
- balance sheet equity data:
- debt and solvency information:
Total Debt to Equity Ratio Wave Life Sciences|WVE - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Wave Life Sciences Ltd.|WVE - Company Aggregate Debts|Debts to Book Value Wave Life Sciences Ltd.|WVE - Company Long-Term Debt|Company Short-Term Indebtedness Wave Life Sciences|Quick Liquidity Indicator wavelifesciences.com
- net income and valuation multiples indicators:
WVE - Net Profit|Expected Net Profit Wave Life Sciences|WVE - Price to Earnings Ratio|Market Cap to Projected Earnings Wave Life Sciences Ltd.|WVE - Price/Earnings to Growth Multiple|Enterprise Value to EBITDA Ratio Wave Life Sciences Ltd|WVE - Operating profit before deduction of amortization|Earnings per share for the last twelve months Wave Life Sciences|WVE - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months wavelifesciences.com|WVE - Earnings growth in current year|Projected earnings per share growth rate for next year Wave Life Sciences
- revenue and sales proceeds data:
Fundamental valuation:WVE Wave Pharma
The investment attractiveness of Wave Life Sciences (WVE) is based on the development of RNA therapeutics and stable partnership payments in the absence of commercial products. The growth dynamics of EPS compared to the same period last year measure the percentage change in net income per share, allowing for the separation of the inertial impact of agreements from the actual recovery of operating margins and confirming the fundamental resilience of the business.
Main competitors
Tempus AI, Inc (TEM) - Earnings growth in current year|Earnings per share growth in current year Qiagen|IONS: Earnings per share increase in current year|Net earnings per share growth this year RGEN (Repligen)|Expected net earnings per share growth this year Avidity Biosciences Inc|Earnings growth in current year CRSP (crisprtx.com)|WGS: Earnings per share growth this year|RARE: Net earnings per share growth this year|Earnings per share trend in current year BEAM|Sarepta (SRPT) - Earnings per share growth in current year|TWST - Expected net earnings per share growth this year|Earnings per share growth in current year 10x Genomics, Inc.|NTLA: Earnings per share increase in current year|Net earnings per share growth this year STOK (Stoke Corp)|Expected net earnings per share growth this year biolifesolutions.com|Earnings growth in current year MAZE (Maze Therapeutics, Inc.)|Earnings growth in current year Sionna Pharma SION|Prime Medicine Bio - Earnings growth in current year|Earnings per share increase in current year TSHA (Taysha)|QURE: Earnings growth in current year|MGTX - Expected net earnings per share growth this year|Net earnings per share growth this year RGNX|SLDB: Earnings per share increase in current year|Earnings per share growth in current year ocugen.com (OCGN)|Expected net earnings per share growth this year PacBio Corp|Earnings per share growth in current year Benitec Biopharma BNTC|DSGN: Earnings per share growth this year|RCKT - Earnings per share growth in current year|4dmoleculartherapeutics.com (FDMT) - Net earnings per share growth this year|lexeotx.com (LXEO) - Earnings per share growth in current year|Korro Bio, Inc (KRRO) - Earnings growth in current year|EDIT (editasmedicine.com) - Earnings growth in current year|Earnings per share growth this year SLN (silence-therapeutics.com)|Earnings per share growth in current year proqr.com (PRQR)|Codexis - Earnings per share growth this year|Earnings growth in current year SGMO (Sangamo Therapeutics)|Earnings growth in current year nautilus.bio NAUT|Metagenomi Inc. - Earnings growth in current year|DTIL (Precision BioSciences Inc.) - Earnings per share growth this year|GBIO: Earnings growth in current year|Earnings per share growth rate in current year Boundless Bio, Inc (BOLD)|XCUR (Exicure) - Earnings growth in current year|Net earnings per share growth this year Imunon (IMNN)|Earnings growth in current year PHIO|Mustang Bio - Earnings per share growth this year|TransCode Therapeutics, Inc. - Net earnings per share growth this year|Expected net earnings per share growth this year Bionano Genomics, Inc. (BNGO)|APDN - Earnings per share growth in current year|Earnings per share increase in current year BLUE (Bluebird Bio)|ImmunoPrecise (IPA) - Earnings per share growth in current year|OMGA: Net earnings per one share growth for the current year|Earnings per share growth in current year Singular Genomics Systems, Inc.|Earnings growth in current year Regulus Therapeutics, Inc.|Net earnings per share growth this year SYRS (Syros)|TBIO - Earnings per share growth rate in current year|Earnings per share growth in current year TRACON Pharmaceuticals, Inc. TCON|Unity Biotechnology (UBX) - Earnings per share growth rate in current year
